Drug Treatment of Clinically Isolated Syndrome
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73598991" target="_blank" >RIV/61989592:15110/19:73598991 - isvavai.cz</a>
Result on the web
<a href="https://link.springer.com/article/10.1007%2Fs40263-019-00647-x" target="_blank" >https://link.springer.com/article/10.1007%2Fs40263-019-00647-x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s40263-019-00647-x" target="_blank" >10.1007/s40263-019-00647-x</a>
Alternative languages
Result language
angličtina
Original language name
Drug Treatment of Clinically Isolated Syndrome
Original language description
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that leads to inflammation, demyelination and ultimately axonal degeneration. In most cases, it is preceded by its precursor, clinically isolated syndrome (CIS) with conversion rates to clinically definite MS (CDMS) of roughly 20–75%. Neurologists are therefore faced with the challenge of initiating a disease-modifying therapy (DMT) as early as possible to favorably influence the course of the disease. During the past 20 years, a multitude of drugs have been incorporated into our therapeutic armamentarium for MS and CIS. Choosing the right drug for an individual patient is complex and should be based not only on the drug’s overall efficacy to prevent disease progression but also its specific adverse reaction profile, the severity of individual disease courses and, finally, patient compliance in order to adequately weigh associated risks and benefits. Here, we review the available data on the efficacy, safety and tolerability of DMTs tested for CIS and discuss their value regarding a delay of progression to CDMS.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CNS DRUGS
ISSN
1172-7047
e-ISSN
—
Volume of the periodical
2019
Issue of the periodical within the volume
33
Country of publishing house
NZ - NEW ZEALAND
Number of pages
18
Pages from-to
659-676
UT code for WoS article
000475573400004
EID of the result in the Scopus database
2-s2.0-85068829171